A novel dic (17;18) (p13.1;q11.2) with loss of TP53 and BCR/ABL rearrangement in an Imatinib resistant chronic myeloid leukemia
Open Access
- 1 January 2012
- journal article
- Published by Springer Science and Business Media LLC in Molecular Cytogenetics
- Vol. 5 (1), 36
- https://doi.org/10.1186/1755-8166-5-36
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomesOncology Letters, 2010
- Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive diseaseBritish Journal of Haematology, 2010
- Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Blood, 2009
- Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutationBlood, 2009
- BCR/ABL rearrangement with b3a3 fusion transcript in a case of childhood acute lymphoblastic leukemiaCancer Genetics and Cytogenetics, 2009
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- The biology of CML blast crisisBlood, 2004
- Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylateLeukemia, 2003
- The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemiaExperimental Hematology, 2000
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990